BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06, Briefing.com reports. The company had revenue of $92.80 million for the quarter, compared to analysts' expectations of $85.62 million. During the same period in the prior year, the company earned ($0.28) earnings per share. The firm's revenue was up 34.9% on a year-over-year basis.
BioCryst Pharmaceuticals Price Performance
Shares of BCRX stock traded down $0.01 during midday trading on Tuesday, reaching $5.26. 6,214,087 shares of the company traded hands, compared to its average volume of 3,395,612. The firm's 50 day simple moving average is $4.90 and its two-hundred day simple moving average is $5.45. The firm has a market cap of $1.09 billion, a PE ratio of -4.46 and a beta of 1.96. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.96.
Analysts Set New Price Targets
BCRX has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. JMP Securities upped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "market outperform" rating in a research report on Tuesday. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $14.00.
Get Our Latest Report on BioCryst Pharmaceuticals
About BioCryst Pharmaceuticals
(
Get Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
